The increased GC reaction, augmented antibody levels and protective abilities seen with the Xcl1(Δ1) fusion vaccine are of great interest for the development of many vaccines (41), especially where induction of high titers of neutralizing antibodies are of particular interest, such as influenza or malaria. The gene discussed is XCL1; the disease is malaria.